Genomic signatures to guide the use of chemotherapeutics. - Wikidata - awgldk - TriplyDB

Genomic signatures to guide the use of chemotherapeutics.

Genomic signatures to guide the use of chemotherapeutics.

http://www.wikidata.org/entity/Q34576027

about

An integrated approach to the prediction of chemotherapeutic response in patients with breast cancer MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer Analytic model for academic research productivity having factors, interactions and implications Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer Systems biology applied to vaccine and immunotherapy development Assessment, origin, and implementation of breath volatile cancer markers.Proteomics of ovarian cancer: functional insights and clinical applications Reconstruction of nuclear receptor network reveals that NR2E3 is a novel upstream regulator of ESR1 in breast cancer Unraveling the microenvironmental influences on the normal mammary gland and breast cancer Utilization of genomic signatures to identify phenotype-specific drugs Expression-based in silico screening of candidate therapeutic compounds for lung adenocarcinoma Discovery of IL-18 as a novel secreted protein contributing to doxorubicin resistance by comparative secretome analysis of MCF-7 and MCF-7/Dox Potentially functional SNPs (pfSNPs) as novel genomic predictors of 5-FU response in metastatic colorectal cancer patients A reproducible approach to high-throughput biological data acquisition and integration Parallel evolution under chemotherapy pressure in 29 breast cancer cell lines results in dissimilar mechanisms of resistance Genome-wide profiles of methylation, microRNAs, and gene expression in chemoresistant breast cancer Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans Utilizing the molecular gateway: the path to personalized cancer management.Multigene expression-based predictors for sensitivity to Vorinostat and Velcade in non-small cell lung cancer.The COXEN principle: translating signatures of in vitro chemosensitivity into tools for clinical outcome prediction and drug discovery in cancer.Prospective comparison of clinical and genomic multivariate predictors of response to neoadjuvant chemotherapy in breast cancer.Concordant gene expression signatures predict clinical outcomes of cancer patients undergoing systemic therapy Learning therapeutic lessons from metastasis suppressor proteins.Comparison of global versus epidermal growth factor receptor pathway profiling for prediction of lapatinib sensitivity in bladder cancer.Data mining in genomics Genomancy: predicting tumour response to cancer therapy based on the oracle of genetics.Age-specific differences in oncogenic pathway deregulation seen in human breast tumors Gene expression patterns within cell lines are predictive of chemosensitivity.Gene expression signatures of radiation response are specific, durable and accurate in mice and humans.Immunogenomics and systems biology of vaccines.An approach to analyse the specific impact of rapamycin on mRNA-ribosome association.Identification of a gene signature in cell cycle pathway for breast cancer prognosis using gene expression profiling data.Data-driven methods to discover molecular determinants of serious adverse drug events.Factors influencing the statistical power of complex data analysis protocols for molecular signature development from microarray data A signature-based method for indexing cell cycle phase distribution from microarray profiles.A gene expression predictor of response to EGFR-targeted therapy stratifies progression-free survival to cetuximab in KRAS wild-type metastatic colorectal cancer 3'-end sequencing for expression quantification (3SEQ) from archival tumor samples.Analysis of multiple sarcoma expression datasets: implications for classification, oncogenic pathway activation and chemotherapy resistance A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors.Discovery of molecular subtypes in leiomyosarcoma through integrative molecular profiling.

P2860

Retraction: Genomic signatures to guide the use of chemotherapeutics.

P921

Q21144332-7B5F95CF-BAC4-454A-8587-DCAD00A47FDC Q21195215-777D335A-81B5-4760-B48C-18E3FD413853 Q24273293-D723E33E-75F0-467C-88D3-3B94825A4F5A Q24644185-FC4AEAD0-5482-4374-ACDE-F515E1C5DC01 Q26830374-79430F3A-A7B3-4095-9522-69E9D9E481C9 Q27692565-24AF432A-EBBF-4FB5-A3D4-F3B3F6E92337 Q28082632-11C895BE-1AF6-4B0C-B07D-D59139B7930C Q28114915-67E455C6-329B-484F-93B8-8E06275A5588 Q28473677-301E9DDC-AE9A-4880-B643-0C477A91C4A7 Q28476014-BF189D19-B456-479C-B32C-4D64E08AB9FA Q28476794-02657919-0689-463F-B49E-989361082FD3 Q28477021-11CB7895-B8B3-4609-9B68-33AB9C11ACB2 Q28544740-13F774F0-3EE4-4F12-8253-253851A7DA28 Q28647460-8CD49B54-B4D8-4452-98C8-E6F3CABFB5EB Q28732256-60215B4A-1F3A-4B0C-9BE7-2D1C7488B0FF Q29248638-F6965A81-8F52-4D1E-934D-9CC6CB81397A Q29616204-269D5F55-602F-4A13-8840-1F247A2CA437 Q30371443-2344F877-04D3-47EC-8DEA-6A73F8238283 Q30430515-0A83542C-1025-4616-A84A-2B2B146258FE Q30433023-E0FEFACA-CFC9-4DA9-9F54-D5E53E3ED2FD Q30433483-27B58A6A-4797-44ED-9F82-AE95EA216EE8 Q30434260-39D5A19A-7A54-463D-89DB-48B72E325900 Q30435922-01602F43-3413-401E-994D-8C1C4B0EC769 Q30438089-98CAAD3D-298A-4FA4-A12D-CE12E19CD8C8 Q30440132-7398FFB1-D2BD-49DE-A8A0-1F584BF90370 Q30440216-B47F9BFB-57C2-45F6-9341-7ED2F05F84FB Q33312929-54AC93B3-4DB1-4FCE-B97D-6F0C1981F005 Q33318982-E4E47422-2D47-4896-8445-6AD930BB04B3 Q33326641-C219BE6F-66DC-4CF6-8DB4-841BA5ABDD49 Q33350387-5C4D1E90-461A-4E2D-81DE-1C45A7829A8C Q33357019-00FDA9EA-E374-4FE9-A5EB-1C6B6AF3F68E Q33368855-6B7B0265-6476-475D-81E1-5A85FA00A432 Q33403734-B9330A77-5F9D-4A46-B134-DCEEDF540340 Q33418596-B87427ED-F5FD-4DA4-84EC-8EBC2CB0488D Q33424041-CE302937-8AE5-4AAC-BE0E-72D1498BBDD4 Q33445357-E1C0EF53-8552-4398-B7A2-DB78D8BFBD02 Q33526362-9150E925-2872-4782-8F35-D51EA8CD56EC Q33549674-1EBBCEBB-6D94-41F3-A275-AA760C6CEB35 Q33621880-D96653FE-F8B3-4526-8BA9-5D5C10E06FBB Q33647672-AF930F37-B6D4-4886-89AC-3CE1B881C7A3

P2860

Q55053741-61417342-1133-47FC-BB24-0C858446678D

P921

Genomic signatures to guide the use of chemotherapeutics.

http://www.wikidata.org/entity/Q34576027

description

2006 nî lūn-bûn

@nan

2006 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Genomic signatures to guide the use of chemotherapeutics.

@ast

Genomic signatures to guide the use of chemotherapeutics.

@en

Genomic signatures to guide the use of chemotherapeutics.

@nl

type

label

Genomic signatures to guide the use of chemotherapeutics.

@ast

Genomic signatures to guide the use of chemotherapeutics.

@en

Genomic signatures to guide the use of chemotherapeutics.

@nl

prefLabel

Genomic signatures to guide the use of chemotherapeutics.

@ast

Genomic signatures to guide the use of chemotherapeutics.

@en

Genomic signatures to guide the use of chemotherapeutics.

@nl

P1433

Q34576027-A222A33F-A5E8-4159-B8DB-B8D81E9B394D

P1476

Q34576027-7E320EB3-A8FA-4373-B429-ADE813B817D1

P2093

Q34576027-1620DA9D-2683-4A5F-AD2D-C2E92488ECC7

Q34576027-1AE6E13B-773E-4981-B2B7-C8D5AA60EE2A

Q34576027-4FC13E7A-4581-48DB-BD80-9D8E17D9852D

Q34576027-5019562B-2CD3-4BF0-B35E-2069AD882870

Q34576027-52FD52EB-C28A-48DE-9D67-E8E0D9957D96

Q34576027-546DB760-2662-4A8B-B0AB-DE74DED81216

Q34576027-55AF2D95-EAE6-4331-9319-2F4307FBC3BF

Q34576027-6915DEE5-C52F-471D-8796-2D04631D3151

Q34576027-73F815BB-78FB-451F-A44C-BB40338B5496

Q34576027-86DAB394-C93A-471E-A25B-1C4CDE62E8DE

P2860

Q34576027-F4D0DD81-5582-42EC-962A-1A199A8527AF

P2888

Q34576027-15C44045-4F53-4A3B-883F-1C1168499640

P304

Q34576027-478704DB-72E2-4E61-8618-BA6BFE4517CE

P31

Q34576027-C3CE8757-387E-43D4-9B17-654A52500960

P356

Q34576027-FE947AE8-FCC9-4080-8839-BCC4F4DBBDE2

P407

Q34576027-09F485EC-1B70-4544-A01A-818871F477F2

P433

Q34576027-25A8B29D-140D-454A-B9D3-730E01173365

P478

Q34576027-44296580-8F9D-4219-B786-C924797EDDB1

P50

Q34576027-489979EC-5DA5-4C05-9E6E-67B491277EAF

P577

Q34576027-0EBD2423-AAEB-4931-9FE0-8537ABB4BA7D

P5824

Q34576027-31ED4512-69D5-46B2-B05C-6CA0FEF74872

P698

Q34576027-6106F4D1-4E2B-4CAC-85A2-F29F05D7670A

P921

Q34576027-7E87F1BA-CD69-4AC7-98E9-0E127DBA12D4

P356

P1433

Nature Medicine

P1476

Genomic signatures to guide the use of chemotherapeutics

@en

P2093

Andrea Bild

http://www.w3.org/2001/XMLSchema#string

Andrew Berchuck

http://www.w3.org/2001/XMLSchema#string

Anil Potti

http://www.w3.org/2001/XMLSchema#string

David Harpole

http://www.w3.org/2001/XMLSchema#string

Geoffrey S Ginsburg

http://www.w3.org/2001/XMLSchema#string

Gina Chan

http://www.w3.org/2001/XMLSchema#string

Holly K Dressman

http://www.w3.org/2001/XMLSchema#string

Hope Cottrill

http://www.w3.org/2001/XMLSchema#string

Janiel Cragun

http://www.w3.org/2001/XMLSchema#string

Jeffrey Marks

http://www.w3.org/2001/XMLSchema#string

P2860

Why therapeutic response may not prolong the life of a cancer patient: selection for oncogenic resistance.

P2888

P304

1294-1300

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NM1491

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

P577

2006-10-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5824

Retraction: Genomic signatures to guide the use of chemotherapeutics.

P698

17057710

http://www.w3.org/2001/XMLSchema#string

P921